Home / Education and Training / Training
Complement UK recognises the importance of education and training as a key driver to improve our understanding of complement and related disorders and to inspire a new generation of researchers in this area of growing health importance.

In 2013, Complement UK initiated a programme of industry-funded, cross-centre PhD studentships, further aiming to link compatible research programmes and increase the number of trainees. The initial round of studentships was made possible through an educational agreement between Complement UK and ALEXION PHARMACEUTICALS. The Agreement was to fund four 4-year PhD studentships. The first two students were selected by a panel of international experts to start in October 2013. A further two studentships commenced in October 2014.

In 2015, Alexion agreed to fund a further two four-year studentships. Recruitment will take place in Spring 2016, for an October 2016 start.
New studentship recruiting
Complement PhD studentships
Consultations are currently in progress (2018).
We have had incredible success with this scheme in the past and are keen to welcome industry to express interest in sponsoring a new round of Complement UK studentships

* Build capacity in areas of health importance and competitiveness
* Generate future leaders in the research field
* Enhance delivery of the research goals through interdisciplinary research and training
* Foster an environment where basic and translational science are aligned to patient need

* Four 4-year PhD studentships
* Subject matter may involve any point of the translational pathway, from target identification to developmental studies in man
* Projects will have two supervisors (who will likely be at different Centres), one in each of the disciplines brought together by the research
* If neither of these supervisors is a clinician, then a third clinically recognised supervisor would provide mentorship regarding the clinical context, even for a basic science project

* Project selection and placement would be competitive and strategically aligned with Complement UK goals.

* Visible commitment to research and training in complement
* Medical advance by enabling translational research across a wide base , e.g. Alzheimer’s, HUS, macular degeneration, transplantation
* Opening up corridors to new collaboration in areas of mutual interest
* Coordinated access to trial groups across the UK

FOR MORE INFORMATION, PLEASE CONTACT: Tony Farrar (conrad.farrar@kcl.ac.uk)